Get Live Data

Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in CanadaView Video
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. Syncona Share Price
  4. Syncona Share News
  5. UK Earnings, Trading Statements Calendar - Next 7 Days

Pin to quick picksSyncona Share News (SYNC)

Syncona Information

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.80
Ask: 122.20
Change: -1.60 (-1.31%)
Spread: 1.40 (1.159%)
Open: 120.20
High: 120.80
Low: 120.20
Prev. Close: 122.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Earnings, Trading Statements Calendar - Next 7 Days

Thu, 12th Nov 2020 15:55

Friday 13 November 
Castings PLCHalf Year Results
Monday 16 November 
Kainos Group PLCHalf Year Results
Vodafone Group PLCHalf Year Results
Smiths Group PLCFirst Quarter Results
Diploma PLCFull Year Results
Kingspan Group PLCTrading Statement
MTI Wireless Edge LtdThird Quarter Results
Tuesday 17 November 
Petra Diamonds LtdFull Year Results
Experian PLCHalf Year Results
Schroder Real Estate Investment Trust LtdHalf Year Results
Aggreko PLCTrading Statement
AdEPT Technology Group PLCHalf Year Results
Hibernia REIT PLCHalf Year Results
Telecom Plus PLCHalf Year Results
System1 Group PLCHalf Year Results
Redcentric PLCHalf Year Results
dotdigital Group PLCFull Year Results
Gear4Music PLCHalf Year Results
Ocean Outdoor LtdTrading Statement
Ninety One PLCHalf Year Results
Scapa Group PLCHalf Year Results
Intermediate Capital Group PLCHalf Year Results
Palace Capital PLCHalf Year Results
Homeserve PLCHalf Year Results
Imperial Brands PLCFull Year Results
Big Yellow Group PLCHalf Year Results
Focusrite PLCFull Year Results
Assura PLCHalf Year Results
Energean PLCTrading Statement
Wednesday 18 November 
Speedy Hire PLCHalf Year Results
TBC Bank Group PLCTrading Statement
Tatton Asset Management PLCHalf Year Results
SSE PLCHalf Year Results
British Land PLCHalf Year Results
Equiniti Group PLCTrading Statement
Halfords Group PLCHalf Year Results
DP Eurasia NVTrading Statement
Safestore Holdings PLCTrading Statement
Twentyfour Income Fund LtdHalf Year Results
Spirax-Sarco Engineering PLCTrading Statement
Thursday 19 November 
Card Factory PLCTrading Statement
Halma PLCHalf Year Results
Keller Group PLCTrading Statement
Kingfisher PLCTrading Statement
Investec PLCHalf Year Results
MITIE Group PLCHalf Year Results
Johnson Matthey PLCHalf Year Results
Euromoney Institutional Investor PLCFull Year Results
Royal Mail PLCHalf Year Results
CMC Markets PLCHalf Year Results
Jet2 PLCHalf Year Results
Close Brothers Group PLCTrading Statement
Charles Stanley Group PLCHalf Year Results
Polar Capital Holdings PLCHalf Year Results
Grainger PLCFull Year Results
LondonMetric Property PLCHalf Year Results
Syncona LtdHalf Year Results
Headlam Group PLCTrading Statement
Naked Wines PLCHalf Year Results
Integrated Diagnostics Holdings PLCTrading Statement
  
Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
Today 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more
12345678910

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.